#None #San Diego #Atrium Therapeutics #PRKAG2 Syndrome #ATR 1072

Atrium Therapeutics Initiates Corventis Clinical Trial

Atrium Therapeutics, Inc., a biopharmaceutical company known for its innovative RNA-based therapies for heart conditions, has announced that it has successfully dosed the first patient in the Corventis clinical trial. This landmark study represents the first investigational effort to address the underlying cause of PRKAG2 syndrome, a rare and life-threatening genetic heart condition. This trial, which aims to evaluate the safety and efficacy of the company's lead therapy, ATR 1072, marks a significant milestone not only for Atrium but also for the PRKAG2 community and the broader field of genetic cardiomyopathy.

PRKAG2 syndrome is a progressive form of cardiomyopathy that stems from mutations in the PRKAG2 gene. These mutations provoke an overactive AMP-activated protein kinase (AMPK), resulting in excessive glycogen buildup in heart muscles, which can lead to severe heart failure and, ultimately, sudden cardiac death. Historically, patients diagnosed with this syndrome were limited to management therapies like pacemakers or defibrillators, which only treated the symptoms rather than the cause of the disease.

The Significance of ATR 1072

ATR 1072 employs a pioneering approach using small interfering RNA (siRNA) to silence mutant mRNA, aiming to restore normal AMPK activity. By targeting the root cause of PRKAG2 syndrome rather than just addressing its symptoms, ATR 1072 stands as a beacon of hope for patients and families affected by this debilitating condition. Kathleen Gallagher, President and CEO of Atrium Therapeutics, remarked, “Dosing the first patient in the Corventis clinical trial is a milestone for Atrium and, more importantly, for the PRKAG2 community.” She further emphasized that this trial is a crucial development towards treating genetic cardiomyopathies at their genetic roots.

What the Corventis Trial Entails

The Corventis trial is structured as a Phase 1/2 multicenter clinical study designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of ATR 1072. Approximately 37 participants will be involved, split between two segments of the study:

• - Part A: Multiple ascending dose cohorts to ascertain safety and optimal dose selection.
• - Part B: A single-arm expansion cohort to evaluate efficacy at the recommended Phase 2 dose, focusing on cardiac structure and function.

The primary endpoint is the incidence of treatment-emergent adverse effects, while secondary endpoints will include assessments of PRKAG2 mRNA reduction, siRNA tissue concentrations, and plasma pharmacokinetics. With the expectation of initial proof-of-concept data in the second half of 2027, the anticipation surrounding this trial is palpable.

The Context of Genetic Cardiomyopathy

With current estimates suggesting that there are between 1,000 and 2,000 individuals in the United States living with PRKAG2 syndrome, the need for effective treatments is dire. The prevailing strategy has been symptomatic management, with no approved therapies focusing on the genetic underpinnings of the condition. This innovative trial has the potential to change that narrative, paving the way for disease-modifying treatments.

Atrium Therapeutics is not only focused on PRKAG2 syndrome; it is also developing other investigational therapies for additional rare genetic cardiomyopathies, including ATR 1086 for PLN cardiomyopathy. With its proprietary RNA delivery platform, the company aims to transform the landscape of cardiology treatment.

In conclusion, the initiation of the Corventis trial is a promising step forward in the fight against PRKAG2 syndrome, signaling hope for patients and families alike, as well as for the broader landscape of cardiac research. For ongoing updates and more information, interested parties can visit Corventis Trial Official Site.